Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies.
Fiche publication
Date publication
avril 2020
Journal
Journal of neuroinflammation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Maillart E, Durand-Dubief F, Louapre C, Audoin B, Bourre B, Derache N, Ciron J, Collongues N, de Sèze J, Cohen M, Lebrun-Frenay C, Hadhoum N, Zéphir H, Deschamps R, Carra-Dallière C, Labauge P, Kerschen P, Montcuquet A, Wiertlewski S, Laplaud D, Runavot G, Vukusic S, Papeix C, Marignier R,
Lien Pubmed
Résumé
Longitudinally extensive transverse myelitis (LETM) is classically related to aquaporin (AQP4)-antibodies (Ab) neuromyelitis optica spectrum disorders (NMOSD) or more recently to myelin oligodendrocyte glycoprotein (MOG)-Ab associated disease. However, some patients remain negative for any diagnosis, despite a large work-up including AQP4-Ab and MOG-Ab. Data about natural history, disability outcome, and treatment are limited in this group of patients. We aimed to (1) describe clinical, biological, and radiological features of double seronegative LETM patients; (2) assess the clinical course and identify prognostic factors; and (3) assess the risk of recurrence, according to maintenance immunosuppressive therapy.
Mots clés
Longitudinally extensive transverse myelitis, Neuromyelitis optica, Outcome, Seronegative, Treatment
Référence
J Neuroinflammation. 2020 Apr 23;17(1):128